Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Back

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

Stevenage London London Sutton Preston

Medical Conditions

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This study will evaluate the safety of tobemstomig alone or in combination with tiragolumab compared with atezolizumab in participants with previously untreated, locally advanced or metastatic urothelial cancer (mUC) who are ineligible to receive a platinum containing chemotherapy.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Apr 2023 Dec 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Participants will receive 1200 mg IV atezolizumab Q3W.

Intervention Arm Group : Arm A;

Intervention Type : DRUG
Intervention Description : Participants will receive 600 mg IV tobemstomig Q3W.

Intervention Arm Group : Arm B;Arm C;

Intervention Type : DRUG
Intervention Description : Participants will receive 600 mg IV tiragolumab Q3W.

Intervention Arm Group : Arm C;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Lister Hospital
    Stevenage
    SG1 4AB
  • Royal Marsden Hospital
    London
    SW3 6JJ
  • Barts and the London NHS Trust
    London
    E1 2ES
  • Royal Marsden Hospital (Sutton)
    Sutton
    SM2 5PT
  • Royal Preston Hosptial
    Preston
    PR2 9HT


The study is sponsored by Hoffmann-La Roche



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05645692
Last updated 05 May 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top